• xxx

JAMES, Professor Nicholas David

Professor Nicholas David James BSc (First Class Honours) MBBS PhD FRCP FRCR


Professor James is Consultant in Clinical Oncology at the Queen Elizabeth Hospital Birmingham and Professor of Clinical Oncology at the University of Birmingham.

Prof. James is internationally renowned for his work in Urological Cancer, particularly on the ground-breaking STAMPEDE trial, which has been used to evaluate, to date, 10 different therapies for advanced prostate cancer in more than 11,000 men. He is a regular educational speaker at conferences worldwide, recently including the American Society of Clinical Oncology, European Society of Medical Oncology (ESMO) and European Association of Urologists Annual Meetings. Results from STAMPEDE with both first line docetaxel chemotherapy 1,2 and abiraterone 3,4 have shown that big survival gains can be made by using existing treatments in novel settings. The New England Journal of Medicine in an editorial accompanying the abiraterone results in 2017 described these as “impressive” and an “important advance for …. metastatic prostate cancer” 5. Most recently, the third set of major results from STAMPEDE were presented at ESMO 2018 and published in the Lancet 6. These showed that for men with newly diagnosed metastatic disease of low volume, adding radiotherapy to the prostate to standard drug therapy improved survival times by about 25%.

In the bladder cancer field Prof James has led a series of trials of chemoradiotherapy culminating in the largest randomised trial in the field, published in the New England Journal of Medicine 7, with an accompanying editorial describing the study as “landmark”“practice changing”8. The trial demonstrated that low dose synchronous chemotherapy reduced invasive bladder cancer relapse rates by 43%.

Outside the clinical and research spheres, Prof James is a closely engaged with patient education initiatives. This is best exemplified by a series of music concerts, in collaboration with the world famous saxophonist Courtney Pine, entitled “It’s a Man Thing”. He also co-founded the leading website CancerHelp UK in 1994. In 2002 it became the main patient resource on the Cancer Research UK website.


Key publications: N D James


  1. Vale CL, Burdett S, Rydzewska LH, et al: Addition of docetaxel or bisphosphonates to standard of care in men with localised or metastatic, hormone-sensitive prostate cancer: a systematic review and meta-analyses of aggregate data. Lancet Oncol 17:243-56, 2016
  2. James ND, Sydes MR, Clarke NW, et al: Addition of docetaxel, zoledronic acid, or both to first-line long-term hormone therapy in prostate cancer (STAMPEDE): survival results from an adaptive, multiarm, multistage, platform randomised controlled trial. Lancet 387:1163-77, 2016
  3. Rydzewska LHM, Burdett S, Vale CL, et al: Adding abiraterone to androgen deprivation therapy in men with metastatic hormone-sensitive prostate cancer: A systematic review and meta-analysis. Eur J Cancer 84:88-101, 2017
  4. James ND, de Bono JS, Spears MR, et al: Abiraterone for Prostate Cancer Not Previously Treated with Hormone Therapy. N Engl J Med 377:338-351, 2017
  5. Logothetis C: Improved Outcomes in Men with Advanced Prostate Cancer. N Engl J Med 377:388-390, 2017
  6. Parker CC, James ND, Brawley CD, et al: Radiotherapy to the primary tumour for newly diagnosed, metastatic prostate cancer (STAMPEDE): a randomised controlled phase 3 trial. Lancet, 2018
  7. James ND, Hussain SA, Hall E, et al: Radiotherapy with or without chemotherapy in muscle-invasive bladder cancer. N Engl J Med 366:1477-88, 2012
  8. Shipley WU, Zietman AL: Old drugs, new purpose–bladder cancer turning a corner. N Engl J Med 366:1540-1, 2012
  9. Sydes MR, Parmar MK, Mason MD, et al: Flexible trial design in practice – stopping arms for lack-of-benefit and adding research arms mid-trial in STAMPEDE: a multi-arm multi-stage randomized controlled trial. Trials 13:168, 2012
  10. Sydes MR, Parmar MK, James ND, et al: Issues in applying multi-arm multi-stage methodology to a clinical trial in prostate cancer: the MRC STAMPEDE trial. Trials 10:39, 2009
  11. James ND, Sydes MR, Clarke NW, et al: Systemic therapy for advancing or metastatic prostate cancer (STAMPEDE): a multi-arm, multistage randomized controlled trial. BJU Int 103:464-9, 2009
  12. Parmar MK, Barthel FM, Sydes M, et al: Speeding up the evaluation of new agents in cancer. J Natl Cancer Inst 100:1204-14, 2008


UK Oncology Forum 2024

The UK Oncology Forum is only open to UK healthcare professionals. By choosing to continue to enter the UK Oncology Forum website, you are confirming that you are a UK healthcare professional.